An G et al., 2019: First-in-human, randomized, placebo-controlled single ascending dose study of oxfendazole. It reports rapid absorption, 8.5-11 h half-life, non-linear exposure and no serious adverse events at 0.5-60 mg/kg.
Oxfendazole was rapidly absorbed with a mean plasma half-life ranging from 8.5 to 11 h.
An G et al., 2019: First-in-human, randomized, placebo-controlled single ascending dose study of oxfendazole. It reports rapid absorption, 8.5-11 h half-life, non-linear exposure and no serious adverse events at 0.5-60 mg/kg. Randomized, placebo-controlled, single ascending dose phase 1 trial; N=70 healthy volunteers; United States (University of Iowa and collaborating sites); doses 0.5, 1, 3, 7.5, 15, 30, 60 mg/kg oral oxfendazole; single dose, 14-day follow-up; NCT02234570. Funder: NIAID/NIH (HHSN272200800008C, HHSN272201300020I) and NCATS (U54 TR001356). Declared conflicts: none in the PubMed record. Product: oxfendazole oral suspension, manufacturer not named in the abstract. Comparator: placebo. This is human data for oxfendazole, NOT for fenbendazole. Context: oxfendazole is the sulfoxide metabolite of fenbendazole (JECFA/CVMP). Study type: randomized trial.
